Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973269 | 0.90 | ALDH1A1 (0.41) | KDM4EMAPTGAATUBB1ALDH1A1 | |
| SCHEMBL9196941 | 0.81 | ALDH1A1 (0.48) | KDM4EMAPTGAATUBB1ALDH1A1 | |
| SCHEMBL10981497 | 0.81 | ALDH1A1 (0.42) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL2116816 | 0.78 | ALDH1A1 (0.46) | KDM4EMAPTGAATUBB1ALDH1A1 | |
| SCHEMBL2120318 | 0.77 | KDM4E (0.40) | KDM4EMAPTGAATUBB1ALDH1A1 | |
| SCHEMBL796952 | 0.76 | ALDH1A1 (0.45) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL7494250 | 0.75 | KDM4E (0.42) | KDM4EMAPTGAATUBB1ALDH1A1 | |
| SCHEMBL324648 | 0.74 | CYP1A1 (0.40) | KDM4EMAPTALDH1A1KMT2AHPGD | |
| SCHEMBL10980213 | 0.73 | SMN1; SMN2 (0.52) | KDM4EMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL19612335 | 0.73 | ALDH1A1 (0.50) | KDM4EMAPTGAATUBB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2629767-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | Cleveland State University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054417-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | RB1, BCR, NRAS | KDM4E 350/4885MAPT 4774/4885GAA 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.